Login to Your Account

Xenova Enters Potential $63M Deal With Genentech For OX40

By Nuala Moran

Wednesday, April 24, 2002
LONDON - Xenova Group plc signed a deal worth up to US$63 million plus royalties with Genentech Inc. for rights to Xenova’s preclinical OX40 program in immune inflammatory diseases. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription